Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026

CCEP Australia strengthens producer responsibility

Veolia ANZ appoints new CEO

Map reveals hidden UV risk for next-gen solar panels

Ensuring reliable level measurement in tanks with internal obstructions

Australia and US investing in additional critical minerals projects

How to centralise remote access: securing all access to your OT systems

Shining a light on cyber threats hiding on the plant floor

AI system learns to keep warehouse robot traffic running smoothly